Tumour markers in breast cancer

D H Cove; K L Woods; S C Smith; D Burnett; J Leonard; R J Grieve; A Howell

doi:10.1038/bjc.1979.251

Tumour markers in breast cancer

D H Cove, K L Woods, S C Smith, D Burnett, J Leonard, R J Grieve, A Howell

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, alpha subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81% of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide sensitive guide to tumour burden. CEA, lactalbumin and alpha subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.

Original language	English
Pages (from-to)	710-718
Journal	British Journal of Cancer
Volume	40
Issue number	5
DOIs	https://doi.org/10.1038/bjc.1979.251
Publication status	Published - 1 Nov 1979

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.1979.251

http://www.nature.com/articles/bjc1979251

Cite this

@article{aafe5db04baf47da9fbcbd1c4e1f8566,

title = "Tumour markers in breast cancer",

abstract = "The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, alpha subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81% of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide sensitive guide to tumour burden. CEA, lactalbumin and alpha subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.",

author = "Cove, {D H} and Woods, {K L} and Smith, {S C} and D Burnett and J Leonard and Grieve, {R J} and A Howell",

year = "1979",

month = nov,

day = "1",

doi = "10.1038/bjc.1979.251",

language = "English",

volume = "40",

pages = "710--718",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "5",

}

TY - JOUR

T1 - Tumour markers in breast cancer

AU - Cove, D H

AU - Woods, K L

AU - Smith, S C

AU - Burnett, D

AU - Leonard, J

AU - Grieve, R J

AU - Howell, A

PY - 1979/11/1

Y1 - 1979/11/1

N2 - The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, alpha subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81% of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide sensitive guide to tumour burden. CEA, lactalbumin and alpha subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.

AB - The clinical usefulness of 8 potential tumour markers has been evaluated in 69 patients with Stage I and II breast cancer and 57 patients with Stage III and IV. Serum CEA concentrations were raised in 13% of patients with local and 65% of those with advanced breast cancer. In patients with clinical evidence of progression or regression of tumour, serum CEA levels changed appropriately in 83% of cases. Taking 4 of the markers (carcinoembryonic antigen (CEA), lactalbumin, alpha subunit and haptoglobin) serum concentrations of one or more were raised in 33% of patients with local disease and 81% of those with advanced breast cancer. However, marker concentrations were often only marginally raised, and are unlikely to provide sensitive guide to tumour burden. CEA, lactalbumin and alpha subunit were detectable in 68%, 43% and 40% respectively of extracts of primary breast cancers.

U2 - 10.1038/bjc.1979.251

DO - 10.1038/bjc.1979.251

M3 - Article

SN - 0007-0920

VL - 40

SP - 710

EP - 718

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 5

ER -

Tumour markers in breast cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this